Asunaprevir

SKU: orb1302828

Description

Asunaprevir (BMS-650032) is a small molecule inhibitor targeting the hepatitis C virus NS3 protease. It has been utilized in research for both in vitro enzymatic assays and in vivo animal studies to investigate antiviral mechanisms and combination therapies against HCV infection.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Images & Validation

−

Key Properties

−

CAS Number	630420-16-5
MW	748.29
Purity	99.92% (May vary between batches)
Formula	C₃₅H₄₆ClN₅O₉S
SMILES	COc1cnc(O[C@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12
Target	SARS-CoV,HCV Protease
Solubility	H2O:Insoluble;Ethanol:20 mg/mL (26.73 mM);DMSO:250 mg/mL (334.1 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.67 mM)

Bioactivity

−

Target IC50	HCV 1a H77:0.7 nM\|5a (SA13):1.7 nM\|1b J4L6S:0.3 nM\|6a (HK-6A):0.9 nM\|4a (ED43):1.6 nM
In Vivo	Asunaprevir, administered orally at doses ranging from 3-15 mg/kg, exhibits a hepatotropic disposition, evidenced by liver-to-plasma ratios spanning from 40 to 359 across different animal species. Twenty-four hours after administration, liver exposure levels in all evaluated species were at least 110 times greater than the inhibitor EC50 noted against HCV genotype-1 replicons. Read more...
In Vitro	Asunaprevir inhibits the NS3 proteolytic activity of genotype 1a (H77 strain) and genotype 1b (J4L6S strain), with IC50s of 0.7 and 0.3 nM, respectively. The EC50s of ASV against replicons encoding the NS3 protease domains representing genotypes 1a, 1b, and 4a, range from 1.2 to 4.0 nM. Replicon cells are maintained under selective pressure with asunaprevir at concentrations of 10 and 30 times the EC50 values (50 or 150 nM final concentrations, respectively). For genotype 1b resistance selection, replicon cells are maintained in the presence of asunaprevir at 10 or 30 times the EC50 values (30 or 90 nM final concentrations, respectively). Asunaprevir, administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV. Read more...
Cell Research	Cytotoxicity is determined by incubating cells (3,000 to 10,000 cells/well) with serially diluted test compounds or DMSO for 5 days (MT-2 cells) or 4 days (all other cell types). Cell viability is quantitated using an MTS assay for MT-2 or a Cell-Titer Blue reagent assay for HEK-293, HuH-7, HepG2, and MRC5 cells, and 50% cytotoxic concentrations (CC50s) are calculated. Read more...
Animal Research	Mice (n=9 per group; overnight fast) receive Asunaprevir (ASV) by oral gavage (5 mg/kg; a vehicle of PEG-400-ethanol, 9:1). Blood samples (-0.2 mL) are obtained by retro-orbital bleeding at 0.25, 0.5, 1, 3, 6, 8, and 24 h after dosing. Within each group, three animals are bled at 0.25, 3, and 24 h, three at 0.5 and 6 h, and three at 1 and 8 h, resulting in a composite pharmacokinetic profile. Livers and brains are also removed from mice at the terminal sampling points. Rats (n=3 per group; overnight fast) receive ASV (amorphous free acid) by oral gavage (3, 5, 10, and 15 mg/kg) in PEG-400-ethanol (9:1). Serial blood samples (-0.3 mL) are obtained from the jugular vein predosing (0 h) and at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 24, and 48 h post dosing. To assess tissue exposure, rats are orally administered ASV (5 or 15 mg/kg, same vehicle as above), and blood, liver, and heart samples from two rats/group are obtained at 0.17, 0.5, 1, 2, 4, 6, 8, 24, 48, and 72 h after dosing. Read more...

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

inhibit, Inhibitor, HCV, HCV Protease, HCV NS3/4A protease, HCVProtease, Hepatitis C virus, BMS650032, BMS-650032, BMS 650032, Asunaprevir, SARS-CoV, SARSCoV, SARS coronavirus

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

124250787 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Asunaprevir (orb1302828)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Purity:	>98% (HPLC)
CAS Number:	630420-16-5
MW:	748.3
Formula:	C₃₅H₄₆ClN₅O₉S

Asunaprevir

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Asunaprevir [orb1221936]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Asunaprevir (orb1302828)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors